Aurobindo Pharma obtains FTC approval for Lannett acquisition

M&A / JV 19 Jun 2026 · In regulatory review· ✓ Verified

Aurobindo Pharma, India's third-largest pharmaceutical player, has been pursuing the acquisition of Lannett, a US-listed generic pharmaceuticals manufacturer. The FTC approval obtained on 19 June 2026 represents clearance of the mandatory US antitrust review under the Hart-Scott-Rodino (HSR) Act. This is a material milestone but does not conclude all regulatory requirements; Indian foreign investment and sectoral approvals, and final NSE/BSE disclosures remain pending.

Why it mattersFTC clearance is a material closing condition in cross-border pharma M&A; its grant signals the likely absence of US competition objections, but Indian regulatory approvals (FIPB/DPIIT, sectoral) and stock exchange listing approvals remain outstanding.
CounselAurobindo Pharma Limited (Acquiror)
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals